gullapalli

The new entity focuses on the discovery, design and development of RLTs. Credit: PeopleImages.com – Yuri A/Shutterstock. Sanofi and Orano Group subsidiary Orano Med have announced a partnership to enhance the development of next-generation radioligand therapies (RLTs) for rare cancers. […]

Parkinson’s disease is a chronic neurological disorder marked by symptoms such as tremors and muscle rigidity. Credit: chainarong06/Shutterstock. The US Food and Drug Administration (FDA) has approved AbbVie‘s VYALEV (foscarbidopa and foslevodopa) to treat motor fluctuations in adults with advanced

The development agreement will see Fresenius Kabi’s cell therapy processing technologies integrated into Cellular Origins’ robotic platform. Credit: Kotin/Shutterstock. Fresenius Kabi and Cellular Origins have announced a partnership to advance the field of cell and gene therapy (CGT) by automating

Rett syndrome is a rare neurodevelopmental disorder that predominantly affects females. Credit: SewCreamStudio/Shutterstock. Acadia Pharmaceuticals has received marketing authorisation from Health Canada for DAYBUE (trofinetide) to treat Rett syndrome in adult and paediatric patients aged two years and above. Rett

The partnership is set to capitalise on Viatris’ extensive global reach and expertise in the cardiovascular sector. Credit: Jo Panuwat D/Shutterstock. Lexicon Pharmaceuticals has entered a licensing agreement with Viatris, granting the latter exclusive rights to commercialise sotagliflozin in all

The collaboration intends to strengthen both companies’ expertise to develop new radiotherapeutic solutions for cancer. Credit: Frame Stock Footage/Shutterstock. Radiopharm Theranostics (RAD) and AtomVie Global Radiopharma have announced a partnership for the development and manufacturing of 177Lu-BetaBart radioantibody to treat

GI-ARS is a significant radiation toxicity that can result in sepsis and lead to death. Credit: Jo Panuwat D/Shutterstock. Synedgen has announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop its lead therapeutic, MIIST305, targeting

Bladder cancer is the second most common urologic cancer in US men. Credit: SaiArLawKa2/Shutterstock. UroGen Pharma has received the new drug application (NDA) acceptance from the US Food and Drug Administration (FDA) for UGN-102 (mitomycin) for intravesical [directly into the

Efinaconazole’s low binding affinity to keratin enables it to penetrate nails effectively to treat onychomycosis. Credit: Prabodha D Herath/Shutterstock. Almirall has completed the decentralised European regulatory procedure for efinaconazole, a triazole antifungal substance with the trade name Jublia, to treat

Boehringer Ingelheim partners with the WHO Foundation to financially support WHO’s Fourteenth General Programme of Work (2025 to 2028). Credit: PeopleImages.com – Yuri A/Shutterstock. Boehringer Ingelheim, in partnership with the WHO Foundation [an organisation set up to support the World